Advertisement
AXON vs VCYT
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- AXON is delivering roughly 34–35% year-over-year revenue growth but has fallen more than 50% from its 2025 peak amid valuation compression and sector-wide multiple pressure.
- VCYT posts solid double-digit test growth and is debt-free, yet the stock dropped about 25% over the past month on reimbursement and commercialization concerns.
- The two companies operate in entirely different sectors: public safety technology versus oncology diagnostics, making this a contrast of momentum, valuation, and risk profiles.
- Axon's "AI Era" and counter-drone businesses are accelerating bookings, while Veracyte's growth depends on clinical guidelines, payer coverage, and new test launches.
- On relative performance, Axon has shown stronger revenue momentum but deeper drawdowns, while Veracyte offers steadier fundamentals with a smaller market cap and higher beta.
Introduction
Investors comparing AXON and VCYT are effectively weighing two very different growth narratives. Axon Enterprise supplies connected hardware, software, and AI tools to public safety and law enforcement agencies, while Veracyte develops genomic diagnostic tests used to guide cancer care. Both companies are growing revenue at double-digit rates and both have experienced notable share-price swings in recent months. This stock comparison is most relevant to growth-oriented investors who want to understand how sector exposure, valuation, and near-term catalysts shape relative performance and market positioning between a high-multiple hardware-and-software platform and a smaller, faster-scaling diagnostics business.
AXON Overview and Recent Performance
Axon Enterprise (AXON) is a global leader in public safety technology, offering TASER energy devices, body-worn and in-car cameras, drones, digital evidence management, and AI-driven software. The company's ecosystem strategy connects hardware with recurring software and services revenue, creating a "flywheel" that analysts frequently highlight. Recent market activity has been volatile: shares traded near the low $400s and were down roughly 25% year to date after a prolonged drawdown, sitting more than 50% below their 52-week high reached in mid-2025.
Fundamentals, however, remain strong. Recent quarterly results showed revenue growing approximately 34–35% year over year, with management raising its full-year growth outlook. Demand for the AI Era Plan accelerated sharply, counter-drone revenue grew triple digits, and contracted bookings outpaced sales. The company also raised capital through a $1.0 billion zero-coupon convertible note offering. Sentiment has been tempered by concerns about valuation, tariffs pressuring gross margins, and intensifying competition as rivals such as Motorola Solutions invest heavily in adjacent counter-drone and software capabilities.
VCYT Overview and Recent Performance
Veracyte (VCYT) is a global diagnostics company whose platform delivers genomic tests for cancer. Its core franchises are Decipher Prostate, Afirma for thyroid cancer, and Prosigna for breast cancer, alongside a growing pipeline that includes minimal residual disease (MRD) testing via TrueMRD. The company has transitioned to consistent profitability and maintains a strong balance sheet with roughly $485 million in cash and no current debt.
Recent performance tells a story of solid operations meeting cautious market sentiment. Quarterly revenue rose about 15% year over year, with Decipher Prostate and Afirma volumes climbing double digits and adjusted earnings expanding. The company also raised its full-year revenue guidance and launched Prosigna and TrueMRD in the U.S. Despite these catalysts, the stock fell approximately 25% over the past month and carries a beta near 1.9, reflecting above-average volatility. Investors have weighed durable test demand and positive estimate revisions against reimbursement uncertainty, a smaller biopharmaceutical revenue stream, and the early-stage nature of new product launches.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates a focused selection of AI-powered trading bots from a broader universe of hundreds of bots that trade thousands of different tickers. Each robot operates with its own trading style, strategy, timeframe, performance history, statistics, and set of tickers, so no two bots behave alike. Only the bots best suited to current market conditions earn a place in this curated section, helping users filter signal from noise without manual screening. Whether you are monitoring momentum, mean reversion, or trend-following setups, exploring the Trending AI Robots page is a practical way to identify which automated strategies are currently aligned with prevailing market dynamics.
Head-to-Head Comparison
The most fundamental contrast between AXON and VCYT is their end market. Axon serves public safety agencies with a hardware-plus-software model that generates recurring revenue and benefits from large, multi-year contracts. Veracyte serves clinicians and health systems with diagnostic tests whose adoption depends on clinical guidelines, physician ordering patterns, and insurance reimbursement.
On growth, Axon's revenue is expanding roughly twice as fast as Veracyte's, driven by AI, drones, and connected devices. Veracyte grows more moderately but has reached profitability with improving margins and a net-cash position. On valuation and risk, Axon trades at a much higher multiple and has suffered a deeper drawdown from its highs, while Veracyte's smaller market capitalization and high beta make it more sensitive to single-catalyst events such as guideline updates or reimbursement decisions. In short, Axon offers scale and faster growth with higher valuation risk, whereas Veracyte offers a steadier, capital-light model with concentration risk tied to a handful of core tests.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and relative positioning, Tickeron's AI would likely favor AXON in the current environment. Axon demonstrates more consistent and accelerating revenue momentum, stronger booking growth, and multiple active catalysts across AI and counter-drone segments. However, this preference is probabilistic rather than definitive: Axon's premium valuation and deeper drawdown from its peak introduce meaningful volatility risk, while VCYT's profitable, debt-free profile and estimate revisions keep it a credible alternative for investors prioritizing stability and lower absolute valuation. The relative outcome will likely hinge on whether Axon's growth rate can continue to justify its multiple and whether Veracyte's new launches convert into sustained, reimbursed demand.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and VCYT is a StrongBuy.
AXON's RSI Indicator ascends from oversold territory
The RSI Oscillator for AXON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 23 of the 27 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 28 of 39 cases over the following month. The odds of a continued upward trend are 72%.
Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.294) is normal, around the industry mean (4.788). AXON has a moderately high P/E Ratio (170.190) as compared to the industry average of (16.638). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.060) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
VCYT in upward trend: 10-day moving average crossed above 50-day moving average on October 02, 2026
The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VCYT's RSI Indicator exited the oversold zone, 17 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 87 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for VCYT just turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 202 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
VCYT broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VCYT entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. VCYT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.775) is normal, around the industry mean (65.617). P/E Ratio (33.285) is within average values for comparable stocks, (2.429). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
AXON | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 69 | 98 | |
SMR RATING 1..100 | 81 | 75 | |
PRICE GROWTH RATING 1..100 | 62 | 42 | |
P/E GROWTH RATING 1..100 | 44 | 95 | |
SEASONALITY SCORE 1..100 | 75 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VCYT's Valuation (70) in the Biotechnology industry is in the same range as AXON (93). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as VCYT (98). This means that AXON’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as AXON (81). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
VCYT's Price Growth Rating (42) in the Biotechnology industry is in the same range as AXON (62). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for VCYT (95). This means that AXON’s stock grew somewhat faster than VCYT’s over the last 12 months.
| AXON | VCYT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 85% | 7 days ago 85% |
| Stochastic ODDS (%) | 3 days ago 70% | 3 days ago 83% |
| Momentum ODDS (%) | N/A | 3 days ago 83% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 80% |
| TrendWeek ODDS (%) | 3 days ago 76% | 3 days ago 75% |
| TrendMonth ODDS (%) | 3 days ago 71% | 3 days ago 81% |
| Advances ODDS (%) | 3 days ago 74% | 5 days ago 73% |
| Declines ODDS (%) | 7 days ago 70% | 13 days ago 79% |
| BollingerBands ODDS (%) | 3 days ago 76% | 3 days ago 82% |
| Aroon ODDS (%) | 3 days ago 59% | 7 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 6 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 3 bearish.
- VCYT’s TA Score: 6 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +7.71% price change this week, while VCYT (@Medical Specialties) price change was +11.15% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -1.11%. For the same industry, the average monthly price growth was -15.47%, and the average quarterly price growth was -17.72%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.55%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
Reported Earning Dates
AXON is expected to report earnings on Nov 03, 2026.
VCYT is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Aerospace & Defense (-1.11% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Medical Specialties (+1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement